Breast cancer biomarkers and molecular medicine: part II

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Review of Molecular Diagnostics

• Publication date

  2004-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14737159.4.2.169PMID 14995904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Immunohistochemical Study

  2006cited by this paper
• Abnormal expression of MDM-2 in breast carcinomas

  2005cited by this paper
• Prognostic Value of a6(cid:1)34 Integrin Expression in Breast Carcinomas Is Affected by Laminin Production from Tumor Cells’

  2005cited by this paper
• Analyses of microsatellite instability and the transforming growth factor‐β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features

  2004cited by this paper
• Heat shock proteins and drug resistance

  2004cited by this paper
• Matrix Metalloproteinase-2 (MMP-2) is Associated with the Risk for a Relapse in Postmenopausal Patients with Node-Positive Breast Carcinoma Treated with Antiestrogen Adjuvant Therapy

  2004cited by this paper
• Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study

  2004cited by this paper
• Prognostic significance of micrometastatic bone marrow involvement

  2004cited by this paper
• Steroid hormone receptors in breast cancer management

  2004cited by this paper
• TP53 and breast cancer

  2003cited by this paper
• Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.

  2003cited by this paper
• Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.

  2003cited by this paper
• C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

  2003cited by this paper
• Breast cancer biomarkers and molecular medicine

  2003cited by this paper
• Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

  2003cited by this paper
• Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

  2003cited by this paper
• Mode of action of docetaxel - a basis for combination with novel anticancer agents.

  2003cited by this paper
• Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

  2003cited by this paper
• Nipple Aspirate Fluid Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Urokinase-Type Plasminogen Activator Receptor Predicts Breast Cancer Diagnosis and Advanced Disease

  2003cited by this paper
• Advantages and limitations of microarray technology in human cancer

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Gene expression predictors of breast cancer outcomes.

  2003cited by this paper
• Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).

  2003cited by this paper
• Maspin expression in invasive breast cancer: association with other prognostic factors

  2003cited by this paper
• CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

  2002cited by this paper
• Anti-tumor Effects of Letrozole

  2002cited by this paper
• The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.

  2002cited by this paper
• The p53 pathway in breast cancer

  2002cited by this paper
• Biology of Natural Killer Cells in Cancer and Infection

  2002cited by this paper
• Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas.

  2002cited by this paper
• Clinicopathologic implications of E‐cadherin reactivity in patients with lobular carcinoma in situ of the breast

  2002cited by this paper
• p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer.

  2002cited by this paper
• Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer

  2002cited by this paper
• Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.

  2002cited by this paper
• Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.

  2002cited by this paper
• Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance

  2002cited by this paper
• Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

  2002cited by this paper
• Expression of maspin predicts poor prognosis in breast‐cancer patients

  2002cited by this paper
• DNA methylation and breast carcinogenesis

  2002cited by this paper
• An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

  2002cited by this paper
• An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.

  2002cited by this paper
• Update on pharmacogenetics in cancer chemotherapy.

  2002cited by this paper
• Tamoxifen ("Nolvadex"): a review.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Matrix metalloproteinases: a tail of a frog that became a prince

  2002cited by this paper
• Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies

  2002cited by this paper
• P53 gene mutations: case study of a clinical marker for solid tumors.

  2002cited by this paper
• Telomerase as a prognostic marker in breast cancer: high‐throughput tissue microarray analysis of hTERT and hTR

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Decreased nm23 expression, but not Ki-67 labeling index, is significantly correlated with lymph node metastasis of breast invasive ductal carcinoma.

  2002cited by this paper
• Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

  2002cited by this paper
• Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

  2002cited by this paper
• Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

  2002cited by this paper
• Nm23 Gene Product Expression in Invasive Breast Cancer

  2002cited by this paper
• Immunohistochemical Expression of Caspase-3 as an Adverse Indicator of the Clinical Outcome in Human Breast Cancer

  2002cited by this paper
• The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

  2002cited by this paper
• NF-?B as a therapeutic target in cancer

  2002cited by this paper
• NF-κB in cancer: from innocent bystander to major culprit

  2002cited by this paper
• Use of proteomic patterns in serum to identify ovarian cancer.

  2002cited by this paper
• Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer.

  2002cited by this paper
• Microsatellite instability in early-onset breast cancer.

  2002cited by this paper
• NF-kappaB as a therapeutic target in cancer.

  2002cited by this paper
• p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• Lack of prognostic significance of nm23 expression in human primary breast cancer.

  2002cited by this paper
• Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome.

  2002cited by this paper
• Nuclear matrix proteins as biomarkers for breast cancer

  2002cited by this paper
• Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

  2002cited by this paper
• Transcriptional profiling in cancer: the path to clinical pharmacogenomics.

  2001cited by this paper
• Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer.

  2001cited by this paper
• Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

  2001cited by this paper
• The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression

  2001cited by this paper
• Persistent E-Cadherin Expression in Inflammatory Breast Cancer

  2001cited by this paper
• Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negativeatients

  2001cited by this paper
• Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer.

  2001cited by this paper
• Studies of apoptosis in breast cancer

  2001cited by this paper
• HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

  2001cited by this paper
• Telomerase and breast cancer

  2001cited by this paper
• Familial cancer diagnosis.

  2001cited by this paper
• E-cadherin as a prognostic indicator in primary breast cancer

  2001cited by this paper
• p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

  2001cited by this paper
• Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study

  2001cited by this paper
• DNA Instability and Human Disease

  2001cited by this paper
• Using genetic variation to study human disease.

  2001cited by this paper
• The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

  2001cited by this paper
• Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes.

  2001cited by this paper
• Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.

  2001cited by this paper
• Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors.

  2001cited by this paper
• CD44-Mediated Oncogenic Signaling and Cytoskeleton Activation During Mammary Tumor Progression

  2001cited by this paper
• Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype

  2001cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer

  2001cited by this paper
• Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast

  2001cited by this paper
• Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers

  2001cited by this paper
• The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.

  2001cited by this paper
• Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

  2001cited by this paper

• A Kelch domain-containing KLHDC7B and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast cancer cell proliferation via the interferon signaling pathway

  2018cites this paper
• Systematic Glycolytic Enzyme Activity Analysis from Human Serum with PEP Technology.

  2018cites this paper
• Matrix Metalloproteinases in Breast Carcinoma

  2017cites this paper
• Molecular genetics complexity impeding research progress in breast and ovarian cancers

  2017cites this paper
• Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

  2017cites this paper
• Identification of potential serum biomarkers for breast cancer using a functional proteomics technology

  2017cites this paper
• Cadherins: The Superfamily Critically Involved in Breast Cancer.

  2016cites this paper
• Integrative analysis of gene expression and phenotype data

  2015cites this paper
• Protein Modification of Designed MRI Contrast Agents

  2015cites this paper
• Tamoxifen metabolites can target both aromatase and estrogen receptors

  2015cites this paper
• Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade

  2015cites this paper
• Early Biomarkers in Breast Cancer

  2014cites this paper
• Neogenin expression is inversely associated with breast cancer grade in ex vivo

  2014cites this paper
• Improving the prediction of chemotherapeutic sensitivity of tumors in breast cancer via optimizing the selection of candidate genes

  2014cites this paper
• OncoSearch: cancer gene search engine with literature evidence

  2014cites this paper
• Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents

  2013cites this paper
• Breast and Ovarian Cancers

  2012cites this paper
• From DEPARTMENT OF ONCOLOGY AND PATHOLOGY Karolinska Institutet, Stockholm, Sweden PROGNOSTIC AND PREDICTIVE FACTORS IN VIETNAMESE BREAST CANCER: A COMPARISON WITH SWEDISH PATIENTS AND EFFECT ON SURVIVAL VU

  2012cites this paper
• The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial

  2012cites this paper
• Chemical and Biological Strategies for Improving the Sensitivity of SPIO-Enhanced MR Imaging

  2011cites this paper
• Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

  2010cites this paper
• Automated assessment in HER-2/neu immunohistochemical expression of breast cancer

  2010cites this paper
• Biomarkers for Basal-like Breast Cancer

  2010cites this paper
• Automated Quantitative Assessment of HER-2/neu Immunohistochemical Expression in Breast Cancer

  2009cites this paper
• Microfluidic chips for protein differential expression profiling

  2009cites this paper
• Profile of Breast Cancer in a Group of Women in a Developing Country in South Asia: Is There a Difference?

  2009cites this paper
• Integrative analysis of gene expression and phenotype data

  2009cites this paper
• RT 2 Profiler PCR Arrays : Pathway-focused gene expression profiling with qRT-PCR

  2009cites this paper
• PRODUCTION AND CHARACTERIZATION OF ANTI-HER2 MONOCLONAL ANTIBODIES

  2008cites this paper
• Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer

  2008cites this paper
• Medullary breast carcinoma.

  2008cites this paper
• Frequent RASSF1A Gene Promoter Hypermethylation in Breast Cancer

  2008cites this paper
• A comparative study on the effect of integrin subunits beta one and beta three on osteoblast implant interactions

  2008cites this paper
• An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer

  2008cites this paper
• Let-7, miR-125, miR-205, and miR-296 are prospective therapeutic agents in breast cancer molecular medicine

  2008cites this paper
• Application Results : Discovering Unique Gene Expression Profiles Associated with Idiosyncratic Liver Toxicity

  2007cites this paper
• New biomarkers in breast cancer: microRNAs and leptins--where are we now?

  2007cites this paper
• The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

  2007cites this paper
• Estudio comparativo de cáncer de mama y sus factores de riesgo en mujeres mexicanas en México y Estados Unidos.

  2007cites this paper
• Letrozole in the neoadjuvant setting: the P024 trial

  2007cites this paper
• Proteomics and Mass Spectrometry for Cancer Biomarker Discovery

  2007cites this paper
• The molecular genetics of breast cancer and targeted therapy

  2007cites this paper
• Comparative Study of Breast Cancers and their Risk Factors among Mexican Women in Mexico and the US

  2007cites this paper
• Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer

  2006cites this paper
• Looking for Thom's biomarkers with proteomics.

  2006cites this paper
• Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation.

  2006cites this paper
• Microfluidic liquid chromatography system for proteomic applications and biomarker screening.

  2006cites this paper
• Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid

  2006cites this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006cites this paper
• Clinical Trials in the Era of Treatment Tailoring

  2006cites this paper
• Molecular markers for treatment decision

  2006cites this paper
• Clinical trials design and treatment tailoring: general principles applied to breast cancer research.

  2006cites this paper
• Mass Spectrometric Characterization of the MCF7 Cancer Cell Line: Proteome Profile and Cancer Biomarkers

  2006influential citation
• The Healthgrid White Paper

  2005cites this paper
• Clinical cancer proteomics: promises and pitfalls.

  2005cites this paper
• Integrative epidemiology: from risk assessment to outcome prediction.

  2005cites this paper
• Perspectives and challenges of clinical pharmacogenomics in cancer.

  2004cites this paper